Assembly Biosciences Inc. (ASMB)
NASDAQ: ASMBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ASMB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $454.39M
- P/E (TTM)
- 29.59
- EPS (TTM)
- $0.75
- Dividend yield
- None
- 52-week range
- 19.20 – 39.65
- Day range
- 21.87 – 22.79
- Volume / Avg
- 480.92K / 309.38K
- Beta
- —
- Shares outstanding
- 20.48M
52-week range
ASMB stock today
Assembly Biosciences (ASMB) closed at $22.19 on Nov 20, down 1.38% (-$0.31), versus the S&P 500's 3.70% decline. Shares are 44.0% below their 52-week high of $39.65, set on Nov 24, 2025 and 15.6% above the 52-week low of $19.20, near the bottom of the past year's range. ASMB is down 34.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 42.4%.
Assembly Biosciences trades at 29.6x its trailing twelve-month earnings per share of $0.75.
Summary generated from market data by MetaCap's automated system. Methodology
About Assembly Biosciences
Company profileAssembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jason A. Okazaki J.D.
- Headquarters
- South San Francisco, CA
- Employees
- 73
- IPO year
- 2010
- Website
- assemblybio.com
Financial highlights
Full financialsIn fiscal 2025, Assembly Biosciences generated $72.3 million in revenue, up 153.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Assembly Biosciences reported a net loss of $6.1 million, compared with a loss of $40.2 million a year earlier. Operating margin was -16.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $72.30M | $28.52M | $7.16M | $0 | $6.25M |
| Growth | +153.52% | +298.16% | — | -100.00% | -92.09% |
| Net income | $-6.12M | $-40.18M | $-61.23M | $-93.09M | $-129.85M |
| EPS (diluted) | $-0.55 | $-6.69 | $-13.38 | $-23.08 | $-3.00 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$51.20+130.73%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.93 vs $-0.44
- Surprise
- -111.36%
ASMB news
All ASMB news- Assembly Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Recent UpdatesNasdaq
- Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent UpdatesGlobeNewswire
- Assembly Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswire
- Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta VirusGlobeNewswire
Assembly Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GYREGyre Therapeutics Inc. | 4.21 | -6.86% | $460.79M | vs ASMB |
| BLSMBlossomHill Therapeutics Inc. | 14.51 | +0.69% | $461.20M | vs ASMB |
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs ASMB |
| RZLTRezolute Inc. | 3.92 | -6.67% | $465.58M | vs ASMB |
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs ASMB |
| MNPRMonopar Therapeutics Inc. | 69.00 | -1.84% | $467.60M | vs ASMB |
| EVOEvotec SE ADR | 1.32 | -8.97% | $469.11M | vs ASMB |
| KMDAKamada Ltd. | 7.74 | -1.15% | $446.85M | vs ASMB |
Indexes, lists and sector
Assembly Biosciences stock FAQ
What is Assembly Biosciences's stock price today?
ASMB last traded at $22.19 as of Nov 20, 4:00 PM EST, down 1.38% on the day. Prices are delayed at least 15 minutes.
Does Assembly Biosciences pay a dividend?
No. Assembly Biosciences does not currently pay a regular cash dividend.
What is ASMB's P/E ratio?
ASMB trades at a trailing P/E ratio of 29.59.
Who is Assembly Biosciences's CEO?
Mr. Jason A. Okazaki J.D. is the chief executive officer of Assembly Biosciences Inc., which has about 73 employees.
Has ASMB ever split its stock?
Yes. The most recent ASMB stock split was a 1-for-12 split on Feb 12, 2024, one of 2 splits on record.
What is the ASMB 52-week high?
The 52-week high for ASMB is $39.65 and the 52-week low is $19.20. The stock is currently 44.0% below its high.